The Allosteric Antagonist of the Sigma-2 Receptors—Elayta (CT1812) as a Therapeutic Candidate for Mild to Moderate Alzheimer’s Disease: A Scoping Systematic Review. This evidence concerns the gene TMEM97 and early-onset autosomal dominant Alzheimer disease.